Compare IHD & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHD | RPTX |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 92.4M |
| IPO Year | N/A | 2020 |
| Metric | IHD | RPTX |
|---|---|---|
| Price | $6.20 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 27.7K | ★ 808.3K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.49 | $0.89 |
| 52 Week High | $5.47 | $2.30 |
| Indicator | IHD | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 58.92 |
| Support Level | $6.14 | $2.11 |
| Resistance Level | $6.28 | $2.27 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 62.54 | 50.00 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.